01 / Franchise
BetaIntercept™
Type 1 & Type 2 Diabetes
Pancreatic isletsBeta cellsCell injury
Pipeline
Six programs. One platform. Real clinical leverage.
Each program is co-developed with leading academic medical centers under prospective protocols, with evidence designed for regulatory clearance and payer coverage.
Clinical pipeline
Four programs advancing from molecular insight to clinical practice.
Each program is built on the InterceptIQ™ platform, accelerating development through shared chemistry, sequencing, and AI infrastructure.
Filter
Program
01Research
02Validation
03Clinical Studies
04Commercialization
Next milestone
Endocrinology
BetaIntercept™ T1
Type 1 Diabetes
Beta-cell methylation cfDNA
Current
72%
Up next
Pivotal enrollment Q4 '26
JDRFJoslin Diabetes Center
Milestone history
- 2023Analytical validation complete
- 2024Prospective cohort (n=1,840)
- 2026Pivotal study initiation
Metabolic
BetaIntercept™ T2
Type 2 Diabetes & NAFLD
Multi-tissue methylation panel
Current
54%
Up next
Multi-site validation Q2 '26
AASLDMass General Hospital
Milestone history
- 2024Discovery cohort locked
- 2025Analytical validation
- 2026Multi-site clinical validation
Oncology
OncoIntercept™
Pancreatic Cancer (Stage I/II)
Tumor-naive methylation + fragmentomics
Current
62%
Up next
Interim readout H1 '26
Memorial Sloan KetteringJohns Hopkins
Milestone history
- 2024Surveillance cohort initiated
- 2025Interim sensitivity readout
- 2027FDA pre-submission
Neurology
NeuroIntercept™
Alzheimer's & Parkinson's
Cortical-neuron cfDNA (plasma + CSF)
Current
28%
Up next
First-in-human cohort 2026
ADNIMayo Clinic
Milestone history
- 2025Feature discovery (n=420)
- 2026Analytical validation start
- 2028Clinical validation start
Progress reflects internal program milestones; not regulatory status. Hover a row for milestone history.
Program portfolio
Three franchises. One molecular substrate.
Fig. 02 / Program biology
02 / Franchise
OncoIntercept™
Pancreatic cancer · MCED · MRD
Pancreatic tissueTumor microenvironmentLiquid biopsy
03 / Franchise
NeuroIntercept™
Alzheimer's & neurodegeneration
NeuronsSynapsesNeurodegeneration
Program
Description
Discovery
Pre-clinical
Analytical Val.
Clinical Val.
Commercial
Endocrinology
BetaIntercept™ T1
Type 1 Diabetes
Partners: JDRF, Joslin Diabetes Center
Direct measurement of beta-cell death via methylation-specific cfDNA — enabling pre-clinical staging and immunotherapy response monitoring.
CURRENT
Metabolic
BetaIntercept™ T2
Type 2 Diabetes & NAFLD
Partners: AASLD, Mass General Hospital
Multi-tissue metabolic disease staging combining hepatocyte and islet signal with insulin-resistance biomarkers.
CURRENT
Oncology
OncoIntercept™
Pancreatic Cancer
Partners: Memorial Sloan Kettering, Johns Hopkins
Early-stage screening for high-risk populations, designed to detect stage I/II PDAC with high specificity in surveillance cohorts.
CURRENT
Neurology
NeuroIntercept™
Neurodegenerative Disease
Partners: Alzheimer's Disease Neuroimaging Initiative
Cortical-neuron cell-free DNA for early Alzheimer's and Parkinson's detection in plasma and CSF.
CURRENT
Pharma services
InterceptIQ™ RX
Therapeutic Monitoring
Partners: Confidential pharma engagements
Pan-tissue pharmacodynamic readout for first-in-human trials — quantifying on-target cell death and off-target organ stress.
CURRENT
Oncology
OncoIntercept™ MRD
Multi-Cancer MRD
Partners: Stand Up To Cancer
Multi-cancer minimal residual disease detection with tumor-naive methodology, supporting adjuvant treatment decisions.
CURRENT